Astria Therapeutics, Inc.
ATXS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.10 | 0.05 | -0.00 |
| FCF Yield | -16.24% | -29.60% | -20.04% | -62.72% |
| EV / EBITDA | -4.75 | -0.68 | -3.70 | 0.20 |
| Quality | ||||
| ROIC | -34.22% | -34.06% | -24.02% | -24.53% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.94 | 0.84 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.08% | -56.95% | -44.58% | 7.21% |
| Safety | ||||
| Net Debt / EBITDA | 0.58 | 2.11 | 0.37 | 0.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |